Monopar to Present ALXN1840 Data at AASLD
Monopar Therapeutics will present two abstracts on its investigational Wilson disease therapy ALXN1840 at AASLD - The Liver Meeting 2026 in Denver.
Updated on Nov. 2, 2026 in Diseases — General
Monopar Therapeutics will present two abstracts on ALXN1840, its investigational therapy for Wilson disease, at AASLD - The Liver Meeting 2026 in Denver from November 5 to 9, 2026. The presentations include an oral talk on baseline characteristics from the Phase 3 FoCus trial and a poster on molybdenum balance in treated patients.
Why it matters
Wilson disease is a rare inherited disorder caused by mutations in the ATP7B gene that leads to copper accumulation in the body. Data from the Phase 3 trial, if confirmed at the conference, would add to the evidence base for a potential new treatment option for patients worldwide.
The Phase 3 pivotal trial reported that ALXN1840 met its 48-week primary endpoint in both previously treated and untreated patients, with 645 patient-years of follow-up across 266 patients. Wilson disease affects about 1 in 30,000 people worldwide, and approval timing for the therapy remains uncertain.
The players
Monopar Therapeutics
Monopar Therapeutics is the biopharmaceutical company developing ALXN1840 as a potential treatment for Wilson disease.
Frederick K. Askari
Frederick K. Askari is a physician-researcher presenting baseline characteristics data from the Phase 3 FoCus trial of ALXN1840.
Professor Aftab Ala
Professor Aftab Ala is a London-based clinician presenting a poster on molybdenum balance in patients treated with ALXN1840.
The details
Monopar will present an oral talk by Frederick K. Askari on baseline Wilson disease characteristics from the Phase 3 FoCus trial on November 8, plus a poster by Professor Aftab Ala on molybdenum balance on November 5. ALXN1840 works by rapidly mobilizing excess copper into albumin complexes and increasing fecal copper excretion.
Timeline
Nov. 5, 2026: Professor Aftab Ala's poster presentation begins at AASLD 2026.
Nov. 5-9, 2026: AASLD - The Liver Meeting 2026 takes place in Denver.
Nov. 8, 2026: Frederick K. Askari delivers his oral presentation.
Research Landscape
Presenting Phase 3 data at AASLD - The Liver Meeting places ALXN1840 among the liver disease research being reviewed by specialists at the field's main annual conference. The presentations add to the clinical record for copper-chelating and copper-balancing approaches in Wilson disease.
For people living with Wilson disease, the presented data may inform future discussions with specialists about available copper-targeting treatments. Patients and families should discuss any new therapy options with their treating physician, since ALXN1840 is still investigational and not yet approved.
The takeaway
Watch for the posted AASLD presentation materials to see the full baseline and molybdenum balance data. Anyone affected by Wilson disease should keep track of regulatory updates before drawing conclusions about treatment availability.
What happens next
Presentation materials will be posted in the Investors section of Monopar's website after each AASLD presentation on November 5 and November 8, 2026.
Further reading
Learn more about Diseases — General and how rare inherited conditions like Wilson disease are studied.
